Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotions and misinformation that led to significant price inflation of its shares during a specific period [6]. Group 1: Allegations - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6]. - Insiders and affiliates allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6]. - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that inflated the stock price [6]. Group 2: Stock Performance - Charming's share price increased from an initial public offering price of $4.00 to a peak of $29.36 per share, despite no fundamental news justifying such a rise [6]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [6]. Group 3: Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the required information to lift the suspension [6]. Group 4: Legal Process - Investors who purchased Charming shares between October 10, 2025, and November 12, 2025, have until February 17, 2026, to apply to be appointed as lead plaintiff in the lawsuit [6].
CHARMING CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Stockholders that a Class Action Lawsuit Has Been Filed Against Charming Medical Limited and Encourages Investors to Contact the Firm